Community Lipid Testing Could Be a Cost-Effective Route to Preventing Cardiovascular Disease

Cardiovascular disease remains the leading cause of premature death worldwide, yet the screening programs designed to catch it early often fail to reach the people who need them most. In the United Kingdom, the NHS Health Check was created to identify individuals at high risk of preventable conditions such as cardiovascular disease, but uptake has remained stubbornly low. A new economic evaluation published in BMC Health Services Research suggests that moving lipid testing out of clinics and into pharmacies, workplaces and homes could be a cost-effective way to close that gap, potentially reshaping how health systems approach both primary and secondary prevention of the world’s biggest killer.

The study, conducted by health economists at the York Health Economics Consortium together with researchers at the digital diagnostics company PocDoc and Health Innovation North East and North Cumbria, evaluated a community-based lipid testing service known as the PocDoc Health Heart Check. Rather than requiring people to book an appointment with a general practitioner, the service brings a finger-prick lipid test directly to where people already are. The analysis examined five distinct deployment settings: the workplace, general community venues, pharmacies, at-home testing triggered by a pharmacy invitation, and case-finding among people already listed on the UK cardiovascular disease register who may not be adhering to their prescribed medication.

The technical heart of the research is an early economic model comparing PocDoc testing against two standards of care: the NHS Health Check for primary prevention, and primary care medication reviews for secondary prevention among people on the cardiovascular disease register. The model tracked the one-year incremental cost of rolling out the service and projected its lifetime cost-effectiveness using quality-adjusted life years, or QALYs, the standard currency of health economic evaluation. A QALY combines survival with health-related quality of life, allowing analysts to weigh whether the extra benefits of an intervention justify its extra costs. The team applied the widely used National Institute for Health and Care Excellence threshold of £20,000 per QALY gained, meaning any intervention whose incremental cost-effectiveness ratio falls below that figure is considered a worthwhile use of National Health Service resources.

The short-term findings reveal an interesting economic tension. On a per-person basis, the PocDoc test itself costs less than an NHS Health Check, largely because the streamlined community format avoids many of the overheads of a conventional clinical appointment. However, the very feature that makes the service attractive, its higher uptake, drives short-term costs upward. When more people show up for testing, the health system pays for more tests in the first year, even before any downstream benefits materialize. The model found that the incremental cost compared with standard care ranged from £6.08 to £36.66 per person in the short term, depending on the setting in which the testing was deployed.

Those modest upfront costs, however, translate into substantial long-term value. Over a lifetime horizon, the evaluation found that PocDoc testing was a cost-effective use of resources in all five settings examined. The incremental cost-effectiveness ratio ranged from £1,915 to £7,884 per QALY, comfortably below the £20,000 per QALY decision threshold. In plain terms, for every additional year of healthy life the service generates, the health system pays only a fraction of what it would typically be willing to spend. The workplace, community, pharmacy and at-home settings all cleared the cost-effectiveness bar for primary prevention, while case-finding on the cardiovascular disease register offered a cost-effective alternative to medication reviews for people who are non-adherent to their lipid-lowering therapy.

The mechanism behind these results is worth unpacking. Community-based testing identifies more people with elevated cholesterol than the current system manages to reach, because it removes the barriers, appointment scheduling, travel and time off work, that suppress uptake of the NHS Health Check. Each additional person identified is a candidate for statin therapy or lifestyle intervention, which over decades reduces the incidence of heart attacks and strokes. Prevented cardiovascular events save lifetime treatment costs and, crucially, preserve quality of life. The model captures this chain of effects, from test uptake through detection, treatment initiation and long-run event reduction, and it is this lifetime horizon where the economics turn decisively favorable.

The researchers did not treat their results as fixed predictions. They subjected the model to deterministic sensitivity analysis, systematically varying key parameters to see how robust the conclusions were under uncertainty. This revealed that the long-term cost-effectiveness results were sensitive to changes in lifetime costs and QALYs, the two quantities that dominate the lifetime horizon. If downstream treatment costs or the quality-of-life gains from avoided cardiovascular events differ from the model’s assumptions, the incremental cost-effectiveness ratio could shift. The team also planned probabilistic sensitivity analysis, which samples across the full uncertainty distributions of all parameters simultaneously, as part of the broader evaluation framework, reflecting the early-stage nature of the model and the need for further validation as real-world data accumulate.

The study was funded through the small business research initiative, a UK program that connects innovative companies with public health challenges, and received ethics approval from the Health Research Authority and Health and Care Research Wales. The authors are transparent about competing interests: two of the researchers are employed by PocDoc as chief strategy officer and chief executive officer, while the York Health Economics Consortium team was commissioned by the company to carry out the work. One author, from Health Innovation North East and North Cumbria, declared no financial interests. This funding structure is common in evaluations of new health technologies, but it means the findings should be read alongside the acknowledged early-stage nature of the model and the need for independent replication.

For health policy, the implications are significant. The NHS Health Check program has long struggled with the paradox that the people least likely to attend clinic-based screening are often those at highest cardiovascular risk, including younger adults, working-age men and communities facing deprivation. Embedding lipid testing in pharmacies, workplaces and community venues offers a route to reach these groups where they live and work, and the economic case suggests the National Health Service would not be paying a premium for that reach. The finding that case-finding among non-adherent patients on the cardiovascular disease register is cost-effective compared with medication reviews is particularly notable, because secondary prevention among this group has been an under-resourced corner of cardiovascular care.

The evaluation is an early economic model, and the authors are careful about what it can and cannot claim. It projects lifetime cost-effectiveness from current evidence on uptake, test performance and treatment effects, and its conclusions rest on assumptions that will be refined as the service generates real-world data on detection rates, treatment initiation and adherence. Still, the headline result, that community-based lipid testing could identify people at high risk of cardiovascular disease at an incremental cost-effectiveness ratio of £1,915 to £7,884 per QALY across all tested settings, positions the approach as one of the more economically compelling screening innovations now under consideration. As health systems worldwide search for ways to prevent cardiovascular disease at scale, the evidence suggests that the pharmacy down the street, the office canteen and the front door may be exactly where the next generation of prevention belongs.

Subject of Research: Economic evaluation of community-based lipid testing for cardiovascular disease prevention

Article Title: Economic evaluation of community-based lipid testing to improve primary and secondary prevention of cardiovascular disease

Article References: Uzdzinska, B., Hex, N., Roest, K., Newton, J., Roest, S., & MacDonald, R. (2026). Economic evaluation of community-based lipid testing to improve primary and secondary prevention of cardiovascular disease. BMC Health Services Research. https://doi.org/10.1186/s12913-026-15838-8

Image Credits: AI Generated

DOI: 10.1186/s12913-026-15838-8

Keywords: lipid testing, cardiovascular disease prevention, economic evaluation, cost-effectiveness, NHS Health Check, QALY, ICER, community screening, health economics, PocDoc, primary prevention, secondary prevention